State Street SPDR S&P Biotech ETF
131 hedge funds and large institutions have $1.62B invested in State Street SPDR S&P Biotech ETF in 2014 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 45 increasing their positions, 46 reducing their positions, and 12 closing their positions.
75% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 12
59% more call options, than puts
Call options by funds: $142M | Put options by funds: $89.2M
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
33% more capital invested
Capital invested by funds: $1.22B → $1.62B (+$399M)
26.63% more ownership
Funds ownership: 360.81% → 387.44% (+27%)
7% more funds holding
Funds holding: 122 → 131 (+9)
2% less repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 46
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$103M |
| 2 |
Mirae Asset Global Investments
Seoul,
South Korea
|
+$79.1M |
| 3 |
Goldman Sachs
New York
|
+$64.2M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$47.5M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$17.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
-$17.2M |
| 2 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
-$12.3M |
| 3 |
SG Americas Securities
New York
|
-$6.48M |
| 4 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$4.64M |
| 5 |
Verition Fund Management
Greenwich,
Connecticut
|
-$4.4M |
XBI Hedge Fund Activity: Q1 2014 in Review
131 of the 3,463 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Biotech ETF (XBI) for Q1 2014, worth a combined $1.62B — up 33% from $1.22B a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new XBI positions and 12 closed out — a net gain of 9 holders — while 45 added to existing stakes and 46 trimmed.
The largest buyer was Credit Suisse, adding an estimated $103M. The largest seller was Barclays, cutting an estimated $17.2M.
- 131 institutional investors held State Street SPDR S&P Biotech ETF (XBI) as of Q1 2014, up from 122 in Q4 2013.
- Funds reported $1.62B of State Street SPDR S&P Biotech ETF stock for Q1 2014, up 33% quarter-over-quarter.
- 21 funds opened new State Street SPDR S&P Biotech ETF positions in Q1 2014 and 12 closed out, a net change of +9 holders.
- The largest State Street SPDR S&P Biotech ETF buyer in Q1 2014 was Credit Suisse, an estimated $103M added.
- The largest State Street SPDR S&P Biotech ETF seller in Q1 2014 was Barclays, an estimated $17.2M sold.
Based on aggregated 13F filings for Q1 2014.